After reports linking Zyvox® to optic and peripheral neuropathy began to surface, the FDA ordered Pfizer to change the “Warnings” section of the labeling for Zyvox® in December, 2002. After the FDA ordered Pfizer to add information about optic and peripheral neuropathy the following language was added to the labeling:

"Postmarketing Experience:
Neuropathy (peripheral, optic) has been reported in patients treated with ZYVOX. Although these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days, these events have also been reported in patients receiving shorter courses of therapy."

In September 2004, the FDA required Pfizer to make additional changes to the Zyvox® labeling by adding more information about optic and peripheral neuropathy to the "Precautions" section of the label. Notably, this additional information recommends that:

"Visual function should be monitored in all patients taking ZYVOX® for extended periods (equal to 3 months) and in all patients reporting new visual symptoms regardless of length of therapy with ZYVOX®."


If you or a loved one suffered from blindness, ongoing visual disturbances, pain or numbness/loss of sensation in the arms or legs while taking Zyvox^®, or if you or a loved suffered from optic or peripheral neuropathy while taking Zyvox^® and you have questions about your legal rights, please click HERE to find out about your potential legal rights.